Bilal Piperdi
- Oncology top 0.5%
- Pulmonary and Respiratory Medicine top 0.5%
- Molecular Biology top 10%
- Epidemiology top 5%
- Cancer Research top 5%
- Co-authors
- Román Pérez-SolerSanatan SarafAnne MoroskyDong‐Wan KimPatrick A. OttSandrine HiretJanice M. MehnertMario E. Lacouture
- Topics
- Lung Cancer Treatments and Mutations (64 papers)Cancer Immunotherapy and Biomarkers (59 papers)Colorectal Cancer Treatments and Studies (30 papers)
- Partner nations
- United StatesSpainAustralia
In The Last Decade
Bilal Piperdi
115 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Oncology 3.9k
- Pulmonary and Respiratory Medicine 2.8k
- Molecular Biology 821
- Epidemiology 529
- Cancer Research 518
Countries citing papers authored by Bilal Piperdi
This map shows the geographic impact of Bilal Piperdi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bilal Piperdi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bilal Piperdi more than expected).
Fields of papers citing papers by Bilal Piperdi
This network shows the impact of papers produced by Bilal Piperdi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bilal Piperdi. The network helps show where Bilal Piperdi may publish in the future.
Co-authorship network of co-authors of Bilal Piperdi
This figure shows the co-authorship network connecting the top 25 collaborators of Bilal Piperdi. A scholar is included among the top collaborators of Bilal Piperdi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bilal Piperdi. Bilal Piperdi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 40 | |
| 2 | Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Studybreakdown → | 165 |
| 3 | 1 | |
| 4 | 5 | |
| 5 | 1 | |
| 6 | 4 | |
| 7 | 2 | |
| 8 | 4 | |
| 9 | 13 | |
| 10 | 3 | |
| 11 | 2 | |
| 12 | 6 | |
| 13 | 0 | |
| 14 | 15 | |
| 15 | 104 | |
| 16 | 11 | |
| 17 | 29 | |
| 18 | 18 | |
| 19 | 44 | |
| 20 | 21 |
About Bilal Piperdi
Bilal Piperdi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 119 papers that have together received 5.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (64 papers), Cancer Immunotherapy and Biomarkers (59 papers) and Colorectal Cancer Treatments and Studies (30 papers). The work is most often cited by research in Oncology (3.9k citations), Pulmonary and Respiratory Medicine (2.8k citations) and Cancer Research (518 citations). Bilal Piperdi has collaborated with scholars based in United States, Spain and Australia. Frequent co-authors include Román Pérez-Soler, Sanatan Saraf, Anne Morosky, Dong‐Wan Kim, Patrick A. Ott, Sandrine Hiret, Janice M. Mehnert, Mario E. Lacouture, Ahmad Daniyal Siddiqui and Armando Santoro. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.